Abstract:[Background] The WNT/β-catenin signaling pathway is a major oncogenic pathway of human hepatocellular carcinoma (HCC). More than 50% of HCCs have aberrant activation of WNT/β-catenin signaling, which are caused by genetic alterations, ligand activation, or cross-activation by other signaling pathways. We hypothesized that activating mutation of CTNNB1, the coding gene of β-catenin, may confer sensitivity to WNT/β-catenin inhibitors in HCC cells. [Materials and Methods] SNU398 is a human HCC cell line harboring a missense somatic mutation in exon 3 of CTNNB1 gene, resulting in S37C mutation. Huh7, HepG2, PLC5, and Hep3B are HCC cells containing no somatic mutations in exon 3 of CTNNB1 gene. HCC cells were treated with various types of WNT/β-catenin pathway inhibitors, including ICG-001 which down-regulates β-catenin/TCF transcriptional activity by interfering the binding of β-catenin with its transcriptional activation complex, XAV939 which targets tankyrases and facilitates degradation of β-catenin, and LGK974 which inhibits Porcupine, an acyltransferase responsible for palmitoylation and secretion of Wnt ligands, and evaluated for in vitro viability by MTT. [Results] ICG-001 as a single agent showed significantly greater anti-proliferation effect in SNU398 than other HCC cells. The 50%-inhibitory concentrations (IC50s) of ICG-001 were 5 μM and >10 μM for SNU398 and other HCC cells, respectively. ICG-001 also induced a more potent suppression of colony- formation, and a more significant increase of subG1 fraction detected by flow cytometry in SNU398 cell than other HCC cells. XAV939 up to 20 μM induced only modest anti-proliferative effect in all HCC cells. However, SNU398 remained the one showing the greatest sensitivity to the growth suppression induced by XAV939. The anti-proliferative effect of LGK974 was modest and showed no significant difference among different HCC cells. [Conclusion] The activating mutation of β-catenin may confer sensitivity to certain WNT/β-catenin pathway inhibitors, such as ICG-001, in HCC cells. (This study was supported by grants NRPB-100CAP1020-2). Citation Format: Hsiao-Hui Lin, Wen-Chi Feng, LI-Chun Lu, Ta-Wen Hsu, Ann-Lii Cheng, Chih-Hung Hsu. Increased sensitivity to Wnt/beta-catenin inhibitors in hepatocellular carcinoma cells harboring activating mutation of beta-catenin. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2625. doi:10.1158/1538-7445.AM2014-2625

A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation

NCOA5 Haploinsufficiency Results in Glucose Intolerance and Subsequent Hepatocellular Carcinoma.

Genetic Polymorphisms of Xrcc1 Gene and Susceptibility to Hepatocellular Carcinoma in Chinese Population

Association Between Polymorphism of C936T in Vascular Endothelial Growth Factor Gene and Type 2 Diabetic Nephropathy

Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma

NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

NCOA5 Deficiency Promotes a Unique Liver Protumorigenic Microenvironment Through P21waf1/cip1 Overexpression, Which is Reversed by Metformin

Cyclooxygenase-2 Gene Polymorphisms and Susceptibility to Hepatocellular Carcinoma

Increased Sensitivity To Wnt/Beta-Catenin Inhibitors In Hepatocellular Carcinoma Cells Harboring Activating Mutation Of Beta-Catenin

A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycytnemia

Aldh2(E487k) Mutation Increases Protein Turnover and Promotes Murine Hepatocarcinogenesis

A Novel HIF2A Mutation Causes Dyslipidemia and Promotes Hepatic Lipid Accumulation

TCF7L2 Rs290487 Variant Modulates Hepatic Glucose Metabolism Via an Allele-Specific Transcriptional and Chromatin Regulation

Impacts of TCF7L2 Gene Polymorphisms on the Susceptibility of Hepatogenous Diabetes and Hepatocellular Carcinoma in Cirrhotic Patients

SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.

Functional Analysis of Hepatic TCF7L2 Gene Polymorphism in Glucose Metabolism by Allele-Specific CRISPR/Cas 9 Gene Editing

Screening and Functional Analysis of Variation in NeuroD1 Gene in Early-Onset Type 2 Diabetic Pedigrees

Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Hyperpolarization-activated Cyclic Nucleotide-Gated Cation Channel 3 Promotes HCC Development in a Female-Biased Manner.

Functional Analyses of the Mutation Nt‐128 T→G in the Hepatocyte Nuclear Factor‐1α Promoter Region in Chinese Diabetes Pedigrees

Long Non-Coding RNA LINC01572 Promotes Hepatocellular Carcinoma Progression via Sponging miR-195-5p to Enhance PFKFB4-Mediated Glycolysis and PI3K/AKT Activation